EHA 2023 | EHA 2023 CLL highlights
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, shares some of the key updates in chronic lymphocytic leukemia (CLL) from EHA 2023, including updates on the efficacy of venetoclax-based regimens in first-line and in the relapsed/refractory (R/R) setting, updates on the mechanisms of resistance to non-covalent BTK inhibitors, and news on the CLL12 study (NCT02863718). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory board: AbbVie, AstraZeneca, BeiGene, Janssen, Lilly Speaker bureau: Octapharma
